FindTrial
Sign In

Clinical application value of accurate assessment of early gastric cancer in predicting lymph node and hematogenous metastasis

Clinical application value of accurate assessment of early gastric cancer in predicting lymph node and hematogenous metastasis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059886
Enrollment
Unknown
Registered
2022-05-13
Start date
2022-04-30
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer

Interventions

Early gastric cancer group vs normal group:None

Sponsors

Shanghai Jiaotong University School of Medicine Affiliated Ruijin Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathologically diagnosed as T1 gastric cancer; 2. In the 15-95 age range; 3. Single primary lesion; 4. Preoperatively staging M0 based on enhanced CT scan and also during operation; 5. Radical gastrectomy with D2 lymphadenectomy.

Exclusion criteria

Exclusion criteria: 1. Used to be diagnosed any other type of malignant tumor; 2. Used to undergo any neoadjuvant chemotherapy or radiotherapy; 3. Lack of patient information; 4. Less than 15 lymph nodes in surgical specimens.

Design outcomes

Primary

MeasureTime frame
Tumor size;Metastatic lymph node;Pathologic type of tumor;—

Secondary

MeasureTime frame
HER2;Lymphatic vessel invasion, LVI;Ulceration;—

Countries

China

Contacts

Public ContactZhenglun Zhu

Shanghai Jiaotong University School of Medicine Affiliated Ruijin Hospital

big8424@126.com+86 13795409982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026